Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. [Translationale Bildgebung des Fibroblastenaktivierungsproteins (FAP) unter Verwendung des neuen Liganden [68Ga]Ga-OncoFAP-DOTAGA]

Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M

Forschungsartikel (Zeitschrift) | Peer reviewed

Zusammenfassung

PURPOSE - METHODS - RESULTS - CONCLUSION; The fibroblast activation protein (FAP) is an emerging target for molecular imaging and therapy in cancer. OncoFAP is a novel small organic ligand for FAP with very high affinity. In this translational study, we establish [68Ga]Ga-OncoFAP-DOTAGA (68Ga-OncoFAP) radiolabeling, benchmark its properties in preclinical imaging, and evaluate its application in clinical PET scanning.; 68Ga-OncoFAP was synthesized in a cassette-based fully automated labeling module. Lipophilicity, affinity, and serum stability of 68Ga-OncoFAP were assessed by determining logD7.4, IC50 values, and radiochemical purity. 68Ga-OncoFAP tumor uptake and imaging properties were assessed in preclinical dynamic PET/MRI in murine subcutaneous tumor models. Finally, biodistribution and uptake in a variety of tumor types were analyzed in 12 patients based on individual clinical indications that received 163 ± 50 MBq 68Ga-OncoFAP combined with PET/CT and PET/MRI.; 68Ga-OncoFAP radiosynthesis was accomplished with high radiochemical yields. Affinity for FAP, lipophilicity, and stability of 68Ga-OncoFAP measured are ideally suited for PET imaging. PET and gamma counting-based biodistribution demonstrated beneficial tracer kinetics and high uptake in murine FAP-expressing tumor models with high tumor-to-blood ratios of 8.6 ± 5.1 at 1 h and 38.1 ± 33.1 at 3 h p.i. Clinical 68Ga-OncoFAP-PET/CT and PET/MRI demonstrated favorable biodistribution and kinetics with high and reliable uptake in primary cancers (SUVmax 12.3 ± 2.3), lymph nodes (SUVmax 9.7 ± 8.3), and distant metastases (SUVmax up to 20.0).; Favorable radiochemical properties, rapid clearance from organs and soft tissues, and intense tumor uptake validate 68Ga-OncoFAP as a powerful alternative to currently available FAP tracers.

Details zur Publikation

FachzeitschriftEuropean Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging)
Jahrgang / Bandnr. / Volume49
Ausgabe / Heftnr. / Issue6
Seitenbereich1822-1832
StatusVeröffentlicht
Veröffentlichungsjahr2022 (31.05.2022)
Sprache, in der die Publikation verfasst istEnglisch
DOI10.1007/s00259-021-05653-0
Link zum Volltexthttps://pmc.ncbi.nlm.nih.gov/articles/PMC9016025/
StichwörterAnimals; Fibroblasts; Gallium Radioisotopes; Humans; Ligands; Mice; Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Tissue Distribution

Autor*innen der Universität Münster

Asmus, Inga
Klinik für Nuklearmedizin
Backhaus, Philipp
Klinik für Nuklearmedizin
Breyholz, Hans-Jörg
Klinik für Nuklearmedizin
Burg, Matthias
Klinik für Radiologie Bereich Lehre & Forschung
Cufe, Juela
Klinik für Nuklearmedizin
Dorten, Paulina Marie
European Institute of Molecular Imaging (EIMI)
Gierse, Florian Werner
Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie - (UKM PHO)
Hermann, Sven
European Institute of Molecular Imaging (EIMI)
Roll, Wolfgang
Klinik für Nuklearmedizin
Schäfers, Michael
Klinik für Nuklearmedizin
Wagner, Stefan
Klinik für Nuklearmedizin
Weckesser, Jochen Matthias
Klinik für Nuklearmedizin